(Q37782025)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734162%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734162%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734162%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Giovanni Davi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734162%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Luciana Mucci

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734162%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

1 reference

24 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734162%20AND%20SRC:MED&resulttype=core&format=json

Internal and emergency medicine

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734162%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734162%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734162%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

203-212

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734162%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11739-010-0440-3

11 February 2020

exact match

0 references

cites work

Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Platelet activation in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Thromboxane A(2) modulates migration, proliferation, and differentiation of adipose tissue-derived mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

The affinities of prostaglandin H2 and thromboxane A2 for their receptor are similar in washed human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Prostanoid receptors: subtypes and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

TP receptor antagonism: a new concept in atherothrombosis and stroke prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Role of prostacyclin in the cardiovascular response to thromboxane A2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endotheli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

A critical review of antiplatelet treatment in peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Isoprostane formation and inhibition in atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Oxidant stress, inflammation and atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Soluble forms of RAGE in internal medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

The coxibs, selective inhibitors of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Aspirin for primary prevention of vascular disease in people with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Determinants of the interindividual variability in response to antiplatelet drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-010-0440-3

Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis

21 January 2018

1 reference

12 December 2020

Leukotrienes potentiate the effects of epinephrine and thrombin on human platelet aggregation

1 reference

12 December 2020

The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus

1 reference

12 December 2020

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

1 reference

12 December 2020

Purification of the thromboxane A2/prostaglandin H2 receptor from human blood platelets

1 reference

12 December 2020

Trial of repeated low-dose aspirin in diabetic angiopathy

1 reference

12 December 2020

Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment

1 reference

12 December 2020

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients

1 reference

12 December 2020

Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation

1 reference

12 December 2020

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

12 December 2020

Soluble RAGE in type 2 diabetes: Association with oxidative stress

1 reference

12 December 2020

Standards of medical care in diabetes--2010.

1 reference

12 December 2020

Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus

1 reference

12 December 2020

Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe

1 reference

12 December 2020

10.1007/S11739-010-0440-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734162%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference